1stOncology™: Cancer Intelligence Service – Page 16305 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

4SC Announces Financial Results for the First Quarter of 2015

On May 7, 2015 4SC AG (Frankfurt, Prime Standard: ISIN DE000A14KL72, VSC), a discovery and development company of targeted small molecule drugs for cancer and autoimmune diseases, reported its consolidated financial results for the first three months of 2015 (1 January – 31 March 2015) (Press release, 4SC, MAY 7, 2015, View Source [SID:1234506571]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Key operating events in Q1 2015 and beyond:

– Resminostat: Successful conclusion of Asia/Pacific (APAC) licensing partnership with Menarini AP, subsidiary of the largest Italian pharma company Menarini Group. 4SC receives upfront payment plus potential further performance-related milestone payments totalling up to approximately EUR 95 million and is entitled to double-digit percentage royalty payments (April 2015).

– Management team strengthened: Dr Susanne Danhauser-Riedl hired as Chief Medical Officer. The medical doctor with many years of experience in clinical practice in haematology/oncology and in the pharmaceutical industry in the field of medical affairs takes over as head of clinical development at 4SC (April 2015).

– Resminostat: New preclinical data on resminostat’s activity as an immunomodulator indicate an attractive further potential of resminostat in combination with immunotherapies such as checkpoint inhibitors (March 2015).

Key financial figures for the first three months of 2015:

– Consolidated revenue boosted by 38% to EUR 1.99 million (Q1 2014: EUR 1.44 million).

– Operating result (EBIT) improved by 37% to EUR -1.33 million (Q1 2014: EUR -2.12 million); loss per share reduced to EUR 0.03 (Q1 2014: EUR 0.04).

– New share capital of EUR 10,169,841.00, as a result of the 1-for-5 reverse stock split, entered in the commercial register (April 2015).

Enno Spillner, CEO of 4SC AG, commented:

"4SC has made a very positive start to 2015. The new licensing partnership with Menarini for resminostat in Asia/Pacific not only strengthens the economic situation but also the overall enterprise value of 4SC. Through Menarini, and together with our existing partner Yakult Honsha for Japan, we have now access for resminostat to the complete APAC region – where 75% of all cases of liver cancer occur."

"This deal also expands our strategic options," Enno Spillner added. "It enables us to consider, for the Western countries, additional development routes for resminostat beyond the liver cancer indication. Haematological niche indications such as e.g. CTCL, where HDAC inhibitors have already demonstrated their efficacy and received approval in the US, are particularly attractive. In Europe, no HDAC inhibitor has been approved yet. Therefore, an approval of a well-tolerated HDAC inhibitor such as resminostat in this setting seems a realistic development option requiring relatively moderate investment of time and resources. In parallel, we are also evaluating development options for our second promising epigenetic oncology compound, 4SC-202. In the person of Dr Susanne Danhauser-Riedl, we were able to acquire an experienced clinician recently who will be providing key momentum for the advancement of our oncology pipeline in her role as Chief Medical Officer at 4SC."

Enno Spillner continued: "Our achievements in the first quarter have been rewarded with positive share performance, and our improved financial results have confirmed our strategy. The focus of our efforts continues to be on promoting the further clinical development of our main value drivers and on securing funding for these endeavours. We are reviewing all our options and are confidently looking ahead to what will certainly be exciting months."

Detailed financial review:

The 4SC Group, which comprises 4SC AG and its wholly-owned subsidiary 4SC Discovery GmbH, reports consolidated figures for the Group in accordance with International Financial Reporting Standards (IFRSs) and financial figures for the two operating segments Development and Discovery & Collaborative Business. For more information on segment reporting, see the full 3-month consolidated financial report at (View Source).

Consolidated revenue was EUR 1.99 million in the first quarter of 2015, a substantial 38% year-on-year increase (Q1 2014: EUR 1.44 million). The increase in revenue was mainly due to allocations to Yakult Honsha of costs to produce the resminostat compound. Revenue in the Development segment consequently increased more than six-fold to EUR 1.42 million (Q1 2014: EUR 0.22 million), while the Discovery & Collaborative Business segment’s revenue fell, partly due to one-off effects in the previous year, by 53% to EUR 0.57 million (Q1 2014: EUR 1.22 million).

The Company’s result from operating activities (EBIT) improved by 37% to EUR -1.33 million in the first quarter of 2015, primarily on the back of higher revenue (Q1 2014: EUR -2.12 million). The loss for the period decreased by 27% to EUR 1.54 million (Q1 2014: EUR 2.12 million). Earnings per share improved to EUR -0.03 (Q1 2014: EUR -0.04).

This results in an average monthly outflow of cash from operations amounting to EUR 0.70 million in the reporting period (2014: EUR 0.71 million). As at 31 March 2015, the Company had cash totalling EUR 2.11 million, compared with EUR 3.20 million as at the close of 2014. In addition, 4SC AG may draw down a further EUR 3 million from the Santo loan and utilise tranches from the Yorkville funding via convertible bonds in an amount of up to EUR 14 million.

Review of operations and performance in Research and Development and the Group in Q1 2015 and beyond and outlook:

Development segment (clinical development activities of 4SC AG)

Resminostat:
After the end of the reporting period, 4SC signed a licence and development agreement for resminostat for the Asia/Pacific ("APAC") region – excluding Japan – with Menarini AP, the Singapore-based subsidiary of the largest Italian pharmaceutical company Menarini Group. For 4SC, the upfront payment received and other potential future performance-related milestone payments amount to up to EUR 95 million. In addition, 4SC will be entitled to double-digit royalties linked to potential future sales.

The development of resminostat in APAC, including China and Japan, is of major strategic importance for 4SC, since one of the most important indications in resminostat’s clinical development programme – HCC – is particularly widespread in this region. To the best of 4SC’s knowledge, over 75% of all cases of liver cancer worldwide occur in the APAC region.

Based on the ongoing and planned activities of the two Asian partners in the indication of liver cancer in Asia, 4SC has begun to evaluate resminostat’s further clinical development in Caucasian patient populations with a focus on other indications in addition to liver cancer. One attractive option would be a haematological niche indication such as cutaneous T-cell lymphoma (CTLC), for example, for which relatively rapid approval could be possible based on a comparatively low outlay of resources and a moderate risk profile. In CTCL, two HDAC inhibitors have already demonstrated efficacy and received market approval in the USA, although such compounds have yet to be approved in Europe.

In addition, 4SC also presented initial preclinical data for resminostat in late March 2015 at the ITOC-2 Conference (Second Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Conference) in Munich. These data point to resminostat’s efficacy as an immunomodulator – a property that 4SC believes would be an outstanding addition to the anti-tumour activity the compound has already demonstrated. Efforts will be made to further confirm these preclinical data.

4SC’s Japanese development partner Yakult Honsha has also made progress in the development of the oral HDAC inhibitor resminostat in the reporting period. The partner is now examining the compound’s efficacy in two randomised Phase II trials in Japan in the indications of advanced liver cancer (HCC) and non-small-cell lung cancer (NSCLC). In both trials, the potential predictive biomarker ZFP64 is also being evaluated in order to be able to identify a patient population with the potential to respond especially well to treatment with resminostat.

4SC-202:
4SC-202, 4SC’s second epigenetic drug candidate currently in clinical development, is an orally available, combined selective inhibitor of the epigenetic targets LSD1 as well as HDAC 1, 2 and 3. This combination is used by 4SC-202 to inhibit the hedgehog and WNT pathways, thus blocking two signalling pathways that play a key role in the development and proliferation of cancer cells and are present in cancer stem cells. To the best of 4SC’s knowledge, 4SC-202 is also the only blocker of the non-canonical, i.e. SMO-independent, hedgehog pathway in clinical development and therefore could be an attractive treatment option for those cancers for which other hedgehog inhibitors have shown no efficacy to date.

Treatment of the last patient in the clinical Phase I TOPAS trial of 4SC-202 was completed in the first quarter of 2015. Last year, this study in heavily pre-treated patients with advanced malignant haematological disorders already returned positive top-line data for pharmacokinetics, safety and tolerability, as well as initial indications of anti-tumour activity on the part of 4SC-202. The data are currently being analysed for the final report, which is expected to be published in mid-2015. On the strength of previous results, the Company is currently engaged in the in-depth analysis of specific options and indications for the further clinical development of 4SC-202. 4SC is also talking to potential financing or industry partners as part of this work.

4SC-205:
In early December 2014, the Company’s third anti-cancer compound – the oral Eg5 kinesin inhibitor 4SC-205 – returned positive top-line data from the Phase I AEGIS trial in patients with advanced solid tumours. In this study, a continuous dosing scheme was used to establish a well-tolerated and potentially effective dose that could possibly be a basis for further clinical development. Treatment of the last patient in the study was completed in the first quarter of 2015. The final study report is now being prepared. 4SC is currently evaluating options for further clinical development with external experts and potential partners.

Discovery & Collaborative Business segment (research at 4SC Discovery GmbH):
The business of 4SC Discovery GmbH based on research collaborations and service partnerships for biotech and pharmaceutical companies and academic institutions evolved further in the first quarter of 2015. In mid-January 2015, the joint BEYOND RESEARCH initiative with the strategic cooperation partner CRELUX reached the first milestone in a drug discovery project for Helmholtz Zentrum München. The first stage of the collaboration with the RỌScue Therapeutics working group for researching new compounds for treatment of degenerative diseases was successfully completed, and the second project phase was started.

In February 2015, a licence agreement was signed with the French subsidiary of the Italian pharmaceutical company Mediolanum by Vienna-based Panoptes Pharma Ges.m.b.H., in which 4SC Discovery GmbH holds a 24.9% stake. Mediolanum acquired the marketing rights to Panoptes’s compound PP-001 in two important European countries. Panoptes received an upfront payment and is entitled to both performance-related milestone payments and royalty payments. PP-001, which was originally discovered by 4SC, is currently in preclinical development as a potential next-generation treatment for serious inflammatory eye diseases such as non-infectious uveitis. 4SC Discovery GmbH will participate from the further development success of PP-001 both with performance-related milestone payments and royalty payments from Panoptes.

It is the aim of 4SC Discovery GmbH to continue the existing research partnerships and licence agreements with pharmaceutical and biotech companies as well as academic institutions and to establish new partnerships to secure financial contributions to the 4SC Group while advancing its own research programmes.

Financial outlook:

4SC had funds of EUR 2.11 million at the end of the first quarter of 2015. In view of short- and medium-term revenue and expense planning and utilisation of the existing convertible note agreement with Yorkville as well as the further opportunity to draw down tranches from the loan agreement with Santo Holding (Deutschland) GmbH, 4SC believes that these funds are sufficient to finance the Company’s operations beyond the first quarter of 2016.

Based on the current financial planning, particular the current planning for revenue that has yet to be met, the Management Board is expecting an average cash burn rate from operations of approx. EUR 0.20 million per month for 2015. New clinical trial starts, such as may follow successful financing, are not included in this forecast and would significantly change it. The same applies in the event of revenue targets being missed.

For 2015, the Management Board anticipates a slight decrease in research and development costs and a further reduction in the consolidated net loss from operations as against 2014 as a result of a renewed drop in operating expenses and a rise in the contributions to earnings at the same time. This is, however, contingent on the Company’s research and development programmes and partnerships continuing to exist and running according to plan and no new clinical studies being started.

In the event of funding being secured and the start of additional clinical Phase II trials – for instance with resminostat and/or 4SC-202 – the Company’s cost and cash flow structure will change markedly, with significant rises in both development expenses and the cash burn rate.

4SC expects to continue posting annual net losses in the short to medium term. For 2015, the Management Board expects 4SC’s research subsidiary to generate a positive cash flow from operations.

Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen

On May 7, 2015 Plexxikon and Merck, through a subsidiary, reported a collaborative clinical trial that will evaluate the combination of PLX3397, Plexxikon’s investigational CSF-1R inhibitor, and KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, which provides the potential for a double blockade of cancer-induced immune suppression (Press release, Merck & Co, MAY 7, 2015, View Source [SID:1234503706]). The Phase 1/2 trial will enroll patients with advanced melanoma and multiple other solid tumors with the goal of determining the safety and tolerability of the combination therapy. The trial is expected to begin enrollment by mid-year.

"We are excited to evaluate PLX3397 in combination with KEYTRUDA, as each agent is designed to attack cancer cells in different ways. Cancer cells use multiple tactics to evade host immune responses, and the combination of these two agents is being investigated to re-activate anti-tumor immunity using distinct and complementary mechanisms," stated Gideon Bollag, Ph.D, chief executive officer of Plexxikon, a member of the Daiichi Sankyo Group. "Importantly, both PLX3397 and KEYTRUDA have potential application in multiple types of cancer."

Know more, wherever you are:
Latest on Melanoma, book your free 1stOncology demo here.

"We are at an important juncture in the advancement of immuno-oncology, and this is why Merck is focused on this area of breakthrough science," stated Dr. Eric Rubin, therapeutic area head, oncology early-stage development, Merck Research Laboratories. "Given the promising data observed with KEYTRUDA and PLX3397, we are eager to see how combining these medicines may be complementary in increasing the immune response."

About PLX3397

PLX3397 is a novel oral small molecule that potently and selectively inhibits CSF-1R, KIT, and mutant FLT3 kinases. CSF1R and KIT regulate key components of both the tumor and its microenvironment (macrophages, osteoclasts, mast cells). In addition to melanoma and other solid tumors to be studied in this collaborative trial, PLX3397 is being evaluated in several other clinical indications, including tenosynovial giant cell tumor (TGCT), historically called pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), breast cancer and glioblastoma. For more information on PLX3397 clinical trials, please visit www.clinicaltrials.gov.

About KEYTRUDA (pembrolizumab)

KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. By binding to the PD-1 receptor and blocking the interaction with the receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.

KEYTRUDA is indicated in the United States at a dose of 2 mg/kg administered as an intravenous infusion over 30 minutes every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Merck is advancing a broad and fast-growing clinical development program for KEYTRUDA with more than 85 clinical trials – across more than 30 tumor types and over 14,000 patients – both as a monotherapy and in combination with other therapies.

Selected Important Safety Information for KEYTRUDA

Pneumonitis occurred in 12 (2.9%) of 411 patients with advanced melanoma receiving KEYTRUDA (the approved indication in the United States), including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients, respectively. Monitor patients for signs and symptoms of pneumonitis. Evaluate suspected pneumonitis with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 pneumonitis.

Colitis (including microscopic colitis) occurred in 4 (1%) of 411 patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients respectively, receiving KEYTRUDA. Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for Grade 4 colitis.

Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411 patients, including a Grade 4 case in 1 (0.2%) patient, receiving KEYTRUDA. Monitor patients for changes in liver function. Administer corticosteroids for Grade 2 or greater hepatitis and, based on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.

Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2 case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving KEYTRUDA. Monitor for signs and symptoms of hypophysitis. Administer corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA for Grade 2; withhold or discontinue for Grade 3; and permanently discontinue KEYTRUDA for Grade 4 hypophysitis.

Nephritis occurred in 3 (0.7%) patients receiving KEYTRUDA, consisting of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of interstitial nephritis with renal failure (0.5%), one Grade 3 and one Grade 4. Monitor patients for changes in renal function. Administer corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.

Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2 or 3 cases in 2 (0.5%) and 1 (0.2%) patients respectively, receiving KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients, including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA. Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid function (at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders. Administer corticosteroids for Grade 3 or greater hyperthyroidism. Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with replacement therapy without treatment interruption and without corticosteroids.

Other clinically important immune-mediated adverse reactions can occur. The following clinically significant, immune-mediated adverse reactions occurred in less than 1% of patients treated with KEYTRUDA: exfoliative dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic anemia, partial seizures arising in a patient with inflammatory foci in brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic neuritis, and rhabdomyolysis.

For suspected immune-mediated adverse reactions, ensure adequate evaluation to confirm etiology or exclude other causes. Based on the severity of the adverse reaction, withhold KEYTRUDA and administer corticosteroids. Upon improvement of the adverse reaction to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or less. Permanently discontinue KEYTRUDA for any severe or Grade 3 immune-mediated adverse reaction that recurs and for any life-threatening immune-mediated adverse reaction.

Based on its mechanism of action, KEYTRUDA may cause fetal harm when administered to a pregnant woman. If used during pregnancy, or if the patient becomes pregnant during treatment, apprise the patient of the potential hazard to a fetus. Advise females of reproductive potential to use highly effective contraception during treatment and for 4 months after the last dose of KEYTRUDA.

For the treatment of advanced melanoma, KEYTRUDA was discontinued for adverse reactions in 6% of 89 patients who received the recommended dose of 2 mg/kg and 9% of 411 patients across all doses studied. Serious adverse reactions occurred in 36% of patients receiving KEYTRUDA. The most frequent serious adverse drug reactions reported in 2% or more of patients were renal failure, dyspnea, pneumonia, and cellulitis.

The most common adverse reactions (reported in ≥20% of patients) were fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%), decreased appetite (26%), constipation (21%), arthralgia (20%), and diarrhea (20%).

The recommended dose of KEYTRUDA is 2 mg/kg administered as an intravenous infusion over 30 minutes every three weeks until disease progression or unacceptable toxicity. No formal pharmacokinetic drug interaction studies have been conducted with KEYTRUDA. It is not known whether KEYTRUDA is excreted in human milk. Because many drugs are excreted in human milk, instruct women to discontinue nursing during treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not been established in pediatric patients.

US FDA grants breakthrough therapy designation for investigational Bcl-2 inhibitor venetoclax in 17p deletion relapsed-refractory chronic lymphocytic leukemia

On May 7, 2015 Roche reported that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation for venetoclax (RG7601, GDC-0199/ABT-199), an investigational medicine being developed in partnership with AbbVie, for the treatment of people who have relapsed or refractory chronic lymphocytic leukemia (CLL) with a genetic abnormality known as 17p deletion (Press release, Hoffmann-La Roche , MAY 7, 2015, View Source [SID:1234503676]). Breakthrough therapy designation is designed to accelerate the development and review of medicines intended to treat serious and life-threatening diseases with evidence showing that the medicines may provide a substantial improvement over current treatment options.

"People who have relapsed or refractory CLL with a 17p deletion typically have a poor prognosis, and do not respond to many currently available treatment options," said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Clinical Development. "We are pleased that the FDA has granted venetoclax Breakthrough Therapy designation and hope this regulatory pathway will help us bring venetoclax to people with this difficult-to-treat disease soon."

Know more, wherever you are:
Latest on Apoptosis in Oncology, book your free 1stOncology demo here.

About CLL and 17p deletion
CLL is a slow-growing cancer of the blood and bone marrow that is generally considered incurable, and is one of the most common adult leukemias worldwide.1,2 Most cases of CLL (95 percent) start in white blood cells called B-cells.1 In certain cases of CLL, a part of chromosome 17 is lost and along with it an important gene that controls apoptosis called p53.3 The 17p deletion is found in 3 to 10 percent of previously untreated cases and approximately 30 to 50 percent of relapsed or refractory cases.4 People with 17p deletion CLL have poor results with conventional chemotherapy regimens and a median life expectancy of less than three years.5

About venetoclax
Venetoclax (RG7601, GDC-0199/ABT-199) is an investigational small molecule designed to selectively bind and inhibit Bcl-2 proteins, an important regulator of a process called programmed cell death, or apoptosis. These proteins are thought to impact how certain blood cancers form, develop and become resistant to treatment. Bcl-2 proteins are expressed at high levels in CLL, non-Hodgkin’s lymphoma (NHL) and in other cancers caused by blood cells called B-cells. Venetoclax is being developed in collaboration with AbbVie and currently being studied in Phase II and Phase III studies for CLL and in Phase I and II studies for several other blood cancers.

Kymab secures US$90 million funding

On May 6, 2015 Kymab ,a leading monoclonal antibody biopharmaceutical company reported that US$50 million is being invested by Woodford Patient Capital Trust plc (LSE:WPCT,"Woodford") and Malin Corporation plc (ISE:MLC, "Malin") (Press release, Kymab, MAY 6, 2015, View Source [SID1234537013]). The additional investment follows the first US$40 million Series B investment from the Wellcome Trust and the Bill & Melinda Gates Foundation to complete a US$90 million Series B financing.

The funds will enable Kymab to maximize the potential of its Kymouse platform and advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies in areas of significant unmet medical need.

In association with the financing, Kymab has added two pre-eminent life science executives to the Board. G. Kelly Martin, former CEO of Elan Corporation, plc, and Director of Malin; and, Dr. Adrian Howd, CEO of Malin.

"We believe Kymab has one of the most comprehensive humanised transgenic antibody platforms underpinned by strong intellectual property," explained Adrian Howd, CEO of Malin. "We are pleased to invest in a world leading antibody company."

Kymab is using the Kymouse transgenic human antibody platform to discover and develop fully human monoclonal antibody drugs. Recent data published in Nature Biotechnology demonstrate that the KymouseTM technology yields an antibody library constituted from 100 trillion different antibodies. From this deep library rare high-quality antibodies can be selected and developed into therapeutics.

"We are delighted to welcome high quality investors of the calibre of Malin and Woodford to Kymab which support our goal to build Kymab into a sustainable biopharmaceutical company," said David Chiswell, Chairman and interim CEO of Kymab. "The funds will be used to maximise the potential of the Kymab pipeline as we develop and commercialise monoclonal antibody medicines for difficult and novel drug targets."

"Kymab has assembled a talented leadership team; an efficient and effective discovery platform with broad application demonstrated by the pipeline of product opportunities already established," commented Kelly Martin, Director of Malin. "We look forward to working with David and his team to fully realize the potential of the Company’s programs, initially in immune-oncology and immunology, and the broader technology platform."

Antibodies are one of the best-selling classes of drugs today; five of the top ten best selling drugs are antibodies. This is because antibodies are natural products with exquisite specificity and potency, and generally have superior safety profiles. The challenge has been to capture the full human antibody repertoire and to recapitulate all its attributes.

10-Q – Quarterly report [Sections 13 or 15(d)]

Supernus has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Supernus, MAY 6, 2015, View Source [SID1234503688]).